Abstract
This study assessed treatment patterns and healthcare resource utilization (HRU) of patients with severe aplastic anemia (SAA) with insufficient response to immunosuppressive therapy (IST). A retrospective chart review was conducted at Dana-Farber Cancer Institute (DFCI), United States, and Hôpital Saint-Louis (HSL), France. Eligible patients were ≥ 18 years old, diagnosed with acquired SAA between January 1, 2006, and July 31, 2016, had insufficient response to IST, and had ≥ 12 months of follow-up post-diagnosis. Overall survival (OS) was estimated using the Kaplan-Meier method. Among the 40 patients, mean age at diagnosis was 44 years and 53% were women. Median follow-up time after SAA diagnosis was 48.3 months. Ninety-five percent of patients received antithymocyte globulin (ATG) as primary therapy prior to hematopoietic stem cell transplant (HSCT). Most common secondary SAA therapies prior to HSCT were eltrombopag (28%) and androgens (15%). Seventy-five percent of patients received HSCT. Prior to HSCT, patients received an average of 2.7 red blood cell (RBC) and 3.3 platelet transfusions per month; patients had 0.9 hospitalizations, 0.4 emergency room visits, and 12.8 office visits per year. Five-year OS was 75%, with infection as the primary cause of death. Additionally, this study provides information on the subgroup of patients receiving eltrombopag which was the most common secondary therapy. This study quantified transfusion and HRU burden associated with SAA and demonstrated high 5-year survival in a recently treated cohort.
Similar content being viewed by others
References
Metcalf D (2012) A promising new treatment for refractory aplastic anemia. N Engl J Med 367(1):74–75. https://doi.org/10.1056/NEJMe1204395
Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA, British Committee for Standards in Haematology (2009) Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 147 (1):43-70. doi:https://doi.org/10.1111/j.1365-2141.2009.07842.x
Aplastic Anemia and MDS International Foundation. Aplastic Anemia. (2017). http://www.aamds.org/diseases/aplastic-anemia. Accessed January 5, 2018
Heimpel H (2000) Epidemiology and aetiology of aplastic anaemia. In: Schrezenmeier HA, Bacigalupo A (eds) Aplastic anaemia: pathophysiology and treatment. Cambridge University Press, Cambridge, UK, pp 97–116
Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, Young NS (2006) The epidemiology of aplastic anemia in Thailand. Blood 107(4):1299–1307. https://doi.org/10.1182/blood-2005-01-0161
Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, Laporte JR, Catalan Group for Study of Agranulocytosis and Aplastic Anemia (2008) Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 93(4):518–523. https://doi.org/10.3324/haematol.12020
Mary JY, Baumelou E, Guiguet M (1990) Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood 75(8):1646–1653
Baslar Z, Aktuglu G, Bolaman Z, Buyukkececi F, Gezer S, Kansu E, Kocak R, Ovali E, Ruacan S, Sargin D, Tunali A, Tuzuner N, Ulku B (1997) Incidence of aplastic anemia in Turkey: a hospital-based prospective multicentre study. Leuk Res 21(11-12):1135–1139
Valdez JM, Scheinberg P, Young NS, Walsh TJ (2009) Infections in patients with aplastic anemia. Semin Hematol 46(3):269–276. https://doi.org/10.1053/j.seminhematol.2009.03.008
Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120(6):1185–1196. https://doi.org/10.1182/blood-2011-12-274019
Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. https://doi.org/10.1182/blood-2016-08-693481
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC, British Society for Standards in Haematology (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187–207. https://doi.org/10.1111/bjh.13853
Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (2014) Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123(12):1818–1825. https://doi.org/10.1182/blood-2013-10-534743
Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M (2015) Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol 2(9):e367–e375. https://doi.org/10.1016/S2352-3026(15)00147-7
Peffault de Latour R (2016) Transplantation for bone marrow failure: current issues. Hematology Am Soc Hematol Educ Program 2016(1):90–98. https://doi.org/10.1182/asheducation-2016.1.90
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376(16):1540–1550. https://doi.org/10.1056/NEJMoa1613878
Lengliné E, Drénou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, Peffault de Latour R (2018) Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica 103(2):212–220
Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ (2011) Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 52(6):726–735
Jin P, Wang J, Li X, Wang M, Ge M, Zhang J, Huang J, Zhang J, Huang Z, Nie N, Shao Y, Shi J, Zheng Y (2015) Evolution of iron burden in acquired aplastic anemia: a cohort study of more than 3-year follow-up. Int J Hematol 101(1):13–22. https://doi.org/10.1007/s12185-014-1708-6
Zhang X, Li Z, Geng W, Song B, Wan C (2018) Effects and predictive factors of immunosuppressive therapy combined with umbilical cord blood infusion in patients with severe aplastic anemia. Yonsei Med J 59(5):643–651. https://doi.org/10.3349/ymj.2018.59.5.643
Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, Sicre de Fontbrune F, Barraco F, Socie G (2018) Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol 93(5):635–642. https://doi.org/10.1002/ajh.25050
Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H (2013) Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 48(2):168–173. https://doi.org/10.1038/bmt.2012.220
Drugs.com. FDA approves new indication for Promacta (eltrombopag) for severe aplastic anemia. (2014). https://www.drugs.com/newdrugs/fda-approves-new-indication-promacta-eltrombopag-severe-aplastic-anemia-4077.html. Accessed September 16, 2016
Novartis Media Relations. Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia. (2015). https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-new-revolade%C2%AE-use-first-class-therapy-patients. Accessed February 7, 2018
Novartis.com. Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA). (2018). Accessed February 8, 2018
Joshi S, Rose MJ, Stanek JR, O’Brien S (2016) A comparison of resource utilization, cost and mortality in children treated for severe aplastic anemia. Blood 128(22):2333–2333
Gómez-De León A, Colunga-Pedraza PR, Santana-Hernández P, Tarín-Arzaga L, Bugarin-Estrada E, Vázquez-Garza RI, Vázquez-Castillo BE, Palomares-Leal A, García-Camarillo DE, Pezina-Cantú CO, Márquez-Pinedo OO, Gómez-Almaguer D (2018) Outpatient hematology visits as a measure of disease burden: insights from a university hospital in Mexico. Paper presented at the International Society of Hematology (ISH), XXXVII World Congress, Vancouver, BC, Canada,
Gill H, Leung GM, Lopes D, Kwong YL (2017) The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol 176(6):991–994. https://doi.org/10.1111/bjh.14024
US National Library of Medicine. Study of romiplostim (AMG531) in subjects with aplastic anemia. https://clinicaltrials.gov/ct2/show/NCT02773290.
Acknowledgements
The authors would like to thank Yvonne Soohoo from Dana-Farber Cancer Institute and Tiana Andriamasy from Hôpital Saint-Louis for their dedicated support with the data collection. The authors also thank Caroline Korves, ScD, of Analysis Group, Inc. for her assistance with developing this manuscript.
Funding
This research was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, US.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
Dr. Huynh, Ms. Ivanova, Mr. Totev, Mr. Bilginsoy, and Dr. Duh are employees of Analysis Group, Inc., a consulting company that has received research funding from Novartis Pharmaceuticals Corporation for this and other studies. Dr. Roy is an employee of Novartis Pharmaceuticals Corporation. Dr. Peffault de Latour and Dr. Antin are employees of institutions, which have received research funding from Novartis Pharmaceuticals Corporation for this study.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors. All study materials were reviewed and approved by local Institutional Review Boards (IRB) in the US (DFCI IRB) and France (CNIL: Commission nationale de l’informatique et des libertés).
Informed consent
Informed consent was not necessary because retrospectively collected medical records were used in the analysis.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Peffault de Latour, R., Huynh, L., Ivanova, J.I. et al. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. Ann Hematol 99, 743–752 (2020). https://doi.org/10.1007/s00277-019-03809-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-019-03809-5